|Bid||0.0000 x 3200|
|Ask||0.0000 x 1300|
|Day's Range||0.1934 - 0.2010|
|52 Week Range||0.1200 - 7.8000|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
TEL AVIV, Israel, Aug. 06, 2018-- InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of carotid artery disease, today announced results ...
Tel Aviv, July 31, 2018-- InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of carotid artery disease, today announced that it will ...
The first COE is at the Augusta Hospital Clinic for Vascular Surgery in Düsseldorf, Germany and is led by Prof. Ralf Kolvenbach, Head of the Cardiovascular Diseases Department and Medical Director of the Catholic Hospitals. Prof. Kolvenbach is one of the leading vascular surgeons in Germany and treats a significant number of patients suffering form carotid artery disease. The second COE is at the Maria Cecilia Hospital, in Cotignola, Italy and is led by Dr. Alberto Cremonesi, Chief of the Cardiovascular Department and a leading interventional cardiologist in Italy, also treating a large number of patients suffering from carotid artery disease.
LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want a free Stock Review on NSPR sign up now at www.wallstequities.com/registration. Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Medical Appliances & Equipment stocks: Globus Medical Inc. (NYSE: GMED), InspireMD Inc. (NYSE AMER: NSPR), Lantheus Holdings Inc. (NASDAQ: LNTH), and LivaNova PLC (NASDAQ: LIVN).
InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the pricing of an underwritten public offering of 33,333,333 units at a price to the public of $0.30 per unit. InspireMD expects to receive aggregate gross proceeds of approximately $10 million from the offering, assuming no exercise of the underwriter’s option to purchase additional securities. Each unit contains one share of common stock (or common stock equivalent) and one Series D warrant to purchase one share of common stock.
Tel Aviv, Israel, June 20, 2018-- InspireMD, Inc., a leader in embolic prevention systems/ thrombus management technologies and neurovascular devices, today announced that CGuard™ EPS was featured at the ...
InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that study results on its CGuard™ EPS were presented at the 10th International Congress of the Polish Society for Vascular Surgery by Dr. Jan Jakub Kesik. Dr Kesik, from Lublin Medical University Hospital, presented an overview study of his experience with CGuard™ EPS, which included 46 patients with 100% procedural success, 0% clinical complications, 0% MACNE, and 0% instent restenosis. The presentation featured the advantages of the CGuard™ EPS covered with the company’s proprietary MicroNet™ PET fiber versus the metallic dual layer Roadsaver® and other conventional carotid stents.
Tel Aviv, Israel, June 11, 2018-- InspireMD, Inc., a leader in embolic prevention systems/ thrombus management technologies and neurovascular devices, today announced that its CGuard™ MicroNet™ covered ...
Jim Barry took the helm as InspireMD Inc’s (AMEX:NSPR) CEO and grew market cap to US$8.32M recently. Understanding how CEOs are incentivised to run and grow their company is anRead More...
WallStEquities.com monitors four Medical Appliances and Equipment stocks, namely: Globus Medical Inc. (NYSE: GMED), Inspire Medical Systems Inc. (NYSE: INSP), InspireMD Inc. (NYSE AMER: NSPR), and LivaNova PLC (NASDAQ: LIVN). Audubon, Pennsylvania headquartered Globus Medical Inc.'s shares recorded a trading volume of 636,640 shares last Friday.
PARADIGM-Extend is the continuation of PARADIGM, an investigator-led clinical study evaluating the use of CGuard™ EPS in patients with symptomatic or asymptomatic carotid artery stenosis with increased stroke risk. The latest results include 251 patients, which is more than double the patient population of 101, which was previously reported in December 2017.
For InspireMD Inc’s (AMEX:NSPR) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. NSPR is exposed toRead More...
LONDON, UK / ACCESSWIRE / May 02, 2018 / Active-Investors.com has just released a free research report on InspireMD, Inc. (NYSE: NSPR). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=NSPR as the Company's latest news hit the wire. On April 30, 2018, the Company announced that it has received regulatory approval and has initiated commercialization of its CGuard™ Embolic Prevention System (EPS) and MGuard Prime™ in Vietnam.
InspireMD Inc (NYSE: NSPR ) stock rallied Monday on news of regulatory approval for its products. What Happened InspireMD announced that it received regulatory approval for its CGuard Embolic Prevention ...
Stock Monitor: Avinger Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 29, 2018 / Active-Investors.com has just released a free research report on InspireMD, Inc. (NYSE: NSPR ). If you want access ...
When InspireMD Inc (AMEX:NSPR) released its most recent earnings update (31 December 2017), I compared it against two factor: its historical earnings track record, and the performance of its industryRead More...